A Phase I Trial of Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2019
Price : $35 *
At a glance
- Drugs Certolizumab pegol (Primary) ; Cisplatin; Pemetrexed
- Indications Adenocarcinoma; Lung cancer
- Focus Adverse reactions
- 23 Apr 2019 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
- 23 Apr 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.
- 31 Aug 2018 Biomarkers information updated